Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
LuCarbo
LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer
- NCT06303713 ↗
- Active, not recruiting
- Dana-Farber Cancer Institute
- Focused
We haven't built an HCP commentary report on LuCarbo (177Lu-PSMA-617 and carboplatin in Prostate Cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on LuCarbo so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 2 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- LuCarbo - a Phase 1a/1b Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer
- Phase
- Phase 1
- Status
- Active, not recruiting
- Conditions
- Prostate Cancer; Metastatic Prostate Cancer; Metastatic Castration-resistant Prostate Cancer
- Interventions
- Carboplatin; 177Lu-PSMA-617
- Arms
- Phase 1A: Dose Escalation · Experimental
- Phase 1B: Dose Expansion · Experimental
- Enrollment
- 37 (estimated)
- Primary outcomes
- Maximum tolerated dose (MTD) or the Recommended Phase 2 dose (RP2D) of carboplatin administered in combination with 177Lu-PSMA-617
- Sponsor
- Dana-Farber Cancer Institute with Novartis
- Start
- May 22, 2024
- Primary completion
- Oct 19, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT06303713 · updated Apr 8, 2026